Aurigene

Aurigene

India - Bangalore
Biotechnology

Focus: Drug discovery

Aurigene is a life sciences company focused on Drug discovery.

OncologyImmunology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

AUR106
Relapse
Phase 1
Clinical Trials (1)
NCT05861947A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Phase 1
Clinical Trials (1)
NCT06761586A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
Phase 1
Clinical Trials (1)
NCT05984147A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
Phase 1
Clinical Trials (1)
NCT06755450Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT05605119First in Human, Dose Escalation, Dose Expansion Study of AUR105
Phase 1
Phase 1
Clinical Trials (1)
NCT05607199A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Phase 1
Clinical Trials (1)
NCT05865002A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Phase 1
Phase 1/2
Clinical Trials (1)
NCT07040059A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 1/2
AUR109 200mg
Ovarian Cancer
Phase 2
Clinical Trials (1)
NCT06760702A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers
Phase 2
Clinical Trials (1)
NCT04207801A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
Phase 2
Phase 2
Clinical Trials (1)
NCT04855721A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2001
Portfolio: 11 clinical trials
Top TAs: Oncology, Immunology
Publications: 25 in PubMed
Therapeutic Area Focus
Oncology
8 pipeline
Immunology
2 pipeline
Marketed
Pipeline